There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pliant Therapeutics (PLRX – Research Report) and Lexicon Pharmaceuticals (LXRX – Research Report) with bullish sentiments.
Pliant Therapeutics (PLRX)
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Pliant Therapeutics, with a price target of $51.00. The company’s shares closed last Tuesday at $21.30.
According to TipRanks.com, Shrader is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pliant Therapeutics with a $48.62 average price target, representing a 125.8% upside. In a report issued on May 18, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $48.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Lexicon Pharmaceuticals (LXRX)
According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of
Currently, the analyst consensus on Lexicon Pharmaceuticals is a Moderate Buy with an average price target of $7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PLRX:
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
- 3 Best Stocks to Buy Now, 5/18/2023, According to Top Analysts
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- PLRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
